Details for New Drug Application (NDA): 209026
NDA 209026 describes POTASSIUM CHLORIDE, which is a drug marketed by Actavis Labs Fl Inc, Adare Pharms Inc, Amneal Pharms, Chartwell Molecular, Glenmark Pharms Ltd, Granules, Lupin, Nesher Pharms, Novel Labs Inc, Padagis Us, Ph Health, Prinston Inc, Strides Pharma, Teva, Tris Pharma Inc, Zydus Pharms, Adaptis, Ajenat Pharms, Amneal, Epic Pharma Llc, Genus, Novitium Pharma, Rubicon Research, Abraxis Pharm, B Braun, Baxter Hlthcare, Fresenius Kabi Usa, Gd Searle Llc, Hospira, Intl Medication, Lilly, Luitpold, Miles, Nexus, Pharma Serve Ny, Watson Labs, Apotex, Ascent Pharms Inc, Aurobindo Pharma, Genus Lifesciences, Macleods Pharms, Pharm Assoc, Quagen, Sciegen Pharms, Taro, Wes Pharma Inc, Aurobindo Pharma Ltd, Breckenridge, Chartwell Rx, Copley Pharm, Guangzhou Novaken, Pharmobedient, Rising, Schering, Sigmapharm Labs Llc, Twi Pharms, Yichang Humanwell, Otsuka Icu Medcl, and Icu Medical Inc, and is included in one hundred and thirty-six NDAs. It is available from seventy-one suppliers. There are two patents protecting this drug. Additional details are available on the POTASSIUM CHLORIDE profile page.
The generic ingredient in POTASSIUM CHLORIDE is calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate. There are five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate profile page.
The generic ingredient in POTASSIUM CHLORIDE is calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate. There are five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the calcium chloride; dextrose; potassium chloride; sodium chloride; sodium lactate profile page.
Summary for 209026
| Tradename: | POTASSIUM CHLORIDE |
| Applicant: | Prinston Inc |
| Ingredient: | potassium chloride |
| Patents: | 0 |
Pharmacology for NDA: 209026
| Mechanism of Action | Osmotic Activity |
| Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |
Suppliers and Packaging for NDA: 209026
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| POTASSIUM CHLORIDE | potassium chloride | CAPSULE, EXTENDED RELEASE;ORAL | 209026 | ANDA | Solco Healthcare LLC | 43547-552 | 43547-552-10 | 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (43547-552-10) |
| POTASSIUM CHLORIDE | potassium chloride | CAPSULE, EXTENDED RELEASE;ORAL | 209026 | ANDA | Solco Healthcare LLC | 43547-553 | 43547-553-10 | 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (43547-553-10) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 8MEQ | ||||
| Approval Date: | Jun 11, 2019 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 10MEQ | ||||
| Approval Date: | Jun 11, 2019 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
